Demand Fundamental	Value	Score	Rating
Qtr/Qtr Revenue Growth	Members Only
Qtr/Qtr Earnings Growth	Members Only
Year/Year Revenue Growth	Members Only
Year/Year Earnings Growth	Members Only
Multi-Year Revenue Growth	Members Only
Multi-Year Earnings Growth	Members Only
Relative PE Ranking	Members Only
Return on Equity	Members Only
Yield	Members Only
Institutional Holding	Members Only
Stock Price	Members Only
Relative Fundamental Ranking	Members Only
Total Score	Members Only

Demand Technical	Value	Score	Rating
Recommended Condition	Members Only
Trading Zone	Members Only
Average Trading Volume	Members Only
Industry Bull/Bear Condition	Members Only
Sector Bull/Bear Condition	Members Only
Current Signal Start Date	Members Only
Total Score	Members Only

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company markets Xyrem, a sodium oxybate oral solution for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy- and Luvox CR extended-release capsules for the treatment of obsessive compulsive disorder. Its product candidates under clinical development include JZP-6, a Phase III pivotal clinical trials completed product for the treatment of fibromyalgia- and JZP-8, an intranasal formulation of clonazepam, which has completed Phase II clinical trial for the treatment of acute repetitive seizures in epilepsy and solid oral dosage forms of sodium oxybate. The company sells its products through specialty sales force targeting sleep specialists, psychiatrists, neurologists, and pulmonologists. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California.